Animal virology

Kindred Biosciences Announces Third Quarter 2020 Financial Results

Retrieved on: 
Monday, November 9, 2020

SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets,today announced financial results for the third quarter ended September 30, 2020 and provided updates on its programs.

Key Points: 
  • SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets,today announced financial results for the third quarter ended September 30, 2020 and provided updates on its programs.
  • For the third quarter of 2020, KindredBio reported net revenues of $1.0 million and a net loss of $12.2 million, or $0.31 per share.
  • On September 16, 2020, KindredBio reported positive results from its pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine parvovirus (CPV).
  • The company recorded royalty revenue of $255,000 in the third quarter and $413,000 for the first nine months of 2020.

OncoMyx Announces Presentation of Preclinical Efficacy Data of Novel Oncolytic Immunotherapy at SITC 2020

Retrieved on: 
Monday, November 9, 2020

OncoMyx Therapeutics , a privately-held oncolytic immunotherapy company, announced the presentation of preclinical data at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting & Preconference Programs ( SITC 2020 ) taking place virtually November 9 to 14.

Key Points: 
  • OncoMyx Therapeutics , a privately-held oncolytic immunotherapy company, announced the presentation of preclinical data at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting & Preconference Programs ( SITC 2020 ) taking place virtually November 9 to 14.
  • The data are the first to demonstrate preclinical therapeutic efficacy of a multi-armed myxoma virotherapy for the treatment of cancer following intravenous (IV) or intratumoral (IT) delivery alone and in combination with immune checkpoint inhibitors.
  • Efficacy of Oncomyxs multi-armed myxoma virotherapy was seen in multiple subcutaneous and metastatic syngeneic tumor models, supporting a pan-tumor treatment approach.
  • The data are also extremely encouraging for IV delivery of our myxoma virotherapies, marking yet another desirable attribute that differentiates myxoma from other oncolytic viruses.

NutraLife BioSciences, Inc. Signs Multi-Year Manufacturing, Distribution and Sales Agreement with Lord Global Corporation Subsidiary for the Launch of Covi-Guard™ Oral Sanitizer

Retrieved on: 
Thursday, November 5, 2020

Covi-Guard is a patent-pending oral mouthwash and spray which may dramatically help to lower the viral and bacterial load in the oral cavity.

Key Points: 
  • Covi-Guard is a patent-pending oral mouthwash and spray which may dramatically help to lower the viral and bacterial load in the oral cavity.
  • According to a recent Penn State University study published in the Journal of Medical Virology, certain mouthwashes and oral rinses may inactivate coronaviruses.
  • This combats virus replication in the mouth and throat and 27Health believes the product may help disrupt the transmission of coronaviruses.
  • Pursuant to the Manufacturing, Distribution, and Sales Agreement, NutraLife will act as 27Healths primary Covi-GuardTMmanufacturer.

NuWave® OxyPure® Air Purifier Found to Reduce Porcine Respiratory Coronavirus Concentration in the Air

Retrieved on: 
Wednesday, October 28, 2020

NuWave, LLC announced an independent study conducted by the University of Minnesota that found the companys OxyPure Air Purifier reduces porcine respiratory coronavirus (PRCV) concentration in the air.

Key Points: 
  • NuWave, LLC announced an independent study conducted by the University of Minnesota that found the companys OxyPure Air Purifier reduces porcine respiratory coronavirus (PRCV) concentration in the air.
  • After each of the three tests, the virus concentration recovered was determined for both upstream and downstream samples.
  • The University of Minnesota has a long history of developing techniques to measure and monitor particle concentrations in the air.
  • The University of Minnesotas test shows that OxyPure significantly reduces PRCV concentration in the air effectively creating a virtually virus-free indoor space.

New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic

Retrieved on: 
Wednesday, October 28, 2020

Paper published by Dr. Steven Quay, M.D., PhD, originates SARS-CoV-2 pandemic to People's Liberation Army Hospital.

Key Points: 
  • Paper published by Dr. Steven Quay, M.D., PhD, originates SARS-CoV-2 pandemic to People's Liberation Army Hospital.
  • The paper documents four patients from the PLA Hospital that have the earliest genetic signature of direct human-to-human coronavirus transmission.
  • The PLA Hospital is three km from WIV and both are located on Line 2 of the Wuhan Metro System.
  • He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus.

New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic

Retrieved on: 
Wednesday, October 28, 2020

The paper documents four patients from the PLA Hospital that have the earliest genetic signature of direct human-to-human coronavirus transmission.

Key Points: 
  • The paper documents four patients from the PLA Hospital that have the earliest genetic signature of direct human-to-human coronavirus transmission.
  • The PLA Hospital is three km from WIV and both are located on Line 2 of the Wuhan Metro System.
  • Line 2 also services the Hunan Seafood Market, previously suggested to be associated with the origin of the pandemic.
  • He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus.

OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference

Retrieved on: 
Monday, October 19, 2020

OncoMyx Therapeutics , a privately-held viral immunotherapy company, announced the presentation of preclinical data at the AACR Virtual Special Conference: Tumor Immunology and Immunotherapy taking place October 19 to 20.

Key Points: 
  • OncoMyx Therapeutics , a privately-held viral immunotherapy company, announced the presentation of preclinical data at the AACR Virtual Special Conference: Tumor Immunology and Immunotherapy taking place October 19 to 20.
  • The data are the first to demonstrate preclinical therapeutic activity alone and in combination with immune checkpoint inhibitors of the companys armed myxoma virotherapy in development to improve cancer treatment.
  • Myxomas large genome is ideal for multi-arming to create a unique precision medicine approach to oncolytic viruses.
  • OncoMyx Therapeutics develops viral immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer.

Xi'an Jiaotong-Liverpool University researcher: COVID-19 coronavirus may have been pre-adapted to infect humans

Retrieved on: 
Thursday, October 15, 2020

Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.

Key Points: 
  • Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.
  • Severe Acute Respiratory Syndrome (SARS) likely used civet cats in its path between bats and humans; Middle East Respiratory Syndrome (MERS) likely came from bats through camels to us.
  • However, a recent study implies the ancestors of the virus that causes COVID-19, SARS-CoV-2, may be predisposed to infect humans.
  • "'Nearly direct' means there is minimum evolution required for a SARS-CoV-2-like bat virus to jump to humans, which also implies the virus may be pre-adapted in bats to infect humans," he said.

Xi'an Jiaotong-Liverpool University researcher: COVID-19 coronavirus may have been pre-adapted to infect humans

Retrieved on: 
Thursday, October 15, 2020

Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.

Key Points: 
  • Bats' physiology is relatively unlike that of humans, so scientists have considered a direct jump, or "zoonotic leap" unlikely generally an animal virus needs to adapt to a human's body before infecting humans.
  • Severe Acute Respiratory Syndrome (SARS) likely used civet cats in its path between bats and humans; Middle East Respiratory Syndrome (MERS) likely came from bats through camels to us.
  • However, a recent study implies the ancestors of the virus that causes COVID-19, SARS-CoV-2, may be predisposed to infect humans.
  • "'Nearly direct' means there is minimum evolution required for a SARS-CoV-2-like bat virus to jump to humans, which also implies the virus may be pre-adapted in bats to infect humans," he said.

Global Wellness Gets High Tech and Creative to Deliver the Safe, Healthy Conference of the Future

Retrieved on: 
Thursday, October 15, 2020

The GWS will require rapid, medically administered COVID-19 testing at check-in, thanks to Premier Family Health of Palm Beach .

Key Points: 
  • The GWS will require rapid, medically administered COVID-19 testing at check-in, thanks to Premier Family Health of Palm Beach .
  • Through a partnership with Health , the Summit will install human-safe, Far-UV light technologies to continuously fight potential coronaviruses in interior conference spaces.
  • "This virus will be with us a long time, and isolation takes a heavy mental health and business toll.
  • About the Global Wellness Summit: The Global Wellness Summit is an invitation-only international gathering that brings together leaders and visionaries to positively shape the future of the $4.5 trillion global wellness economy.